43 Emerging advancements in medical science are reshaping the treatment of brain metastases, a severe complication of cancers such as non-small cell lung cancer (NSCLC), breast cancer, and melanoma. Precision medicine and targeted therapies have become the cornerstones of this transformative era, addressing the long-standing challenge of the blood-brain barrier. The findings were published in the journal Current Neurology and Neuroscience Reports Historically, treatment for brain metastases relied heavily on local interventions such as whole-brain radiation therapy, stereotactic radiosurgery, and neurosurgical procedures. These methods, while beneficial, were limited in their ability to address systemic disease effectively. The advent of small-molecule tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates has shifted this paradigm. By specifically targeting molecular drivers of metastases, these treatments are achieving unprecedented results. For patients with EGFR-mutant NSCLC, osimertinib has emerged as a powerful therapy. Capable of penetrating the blood-brain barrier, this drug has demonstrated extended progression-free survival and enhanced intracranial control. Beyond this, combination therapies, such as amivantamab with lazertinib, are providing alternatives for patients resistant to frontline treatments. This evolution underscores the dynamic nature of NSCLC management. Breast cancer, particularly the HER2-positive subtype, has seen significant breakthroughs with drugs such as tucatinib and trastuzumab deruxtecan. Tucatinib’s ability to specifically target and manage brain metastases has redefined survival outcomes. Meanwhile, trastuzumab deruxtecan’s dual capability to manage both systemic and brain lesions offers hope for comprehensive disease management. For patients with the challenging triple-negative breast cancer subtype, sacituzumab govitecan and datopotamab deruxtecan are pioneering treatments showing promise in clinical trials. The management of melanoma brain metastases has been bolstered by immune checkpoint inhibitors, with nivolumab and ipilimumab demonstrating robust efficacy. These treatments harness the body’s immune system to combat cancer, offering an alternative for patients with limited options. For patients with BRAF-mutant melanoma, combinations of BRAF and MEK inhibitors, including vemurafenib and cobimetinib, are proving highly effective. Despite these advancements, significant hurdles remain. Resistance to targeted therapies, driven by secondary mutations or evolving tumour dynamics, continues to challenge long-term efficacy. Moreover, the variability in response across different genetic profiles of patients highlights the need for personalised treatment strategies. Researchers are actively exploring combination therapies and innovative delivery mechanisms, such as nanoparticles, to enhance drug efficacy and overcome resistance. Future directions in brain metastases treatment are likely to focus on precision medicine. By tailoring treatments based on individual molecular and genetic profiles, medical practitioners aim to refine therapeutic outcomes further. Biomarkers are playing an increasingly vital role in guiding these efforts, helping to identify the most effective interventions for each patient.